Background: International guideline-recommended on-demand treatments for hereditary angioe-
INTRODUCTION
Hereditary angioedema (HAE) is an autosomal dominant disorder characterized by acute episodes of angioedema, which can be intensely distressing, and life-threatening.
1 HAE is a global disease, reported amongst varied ethnicities. Prevalence reports range from 1:10 000 to 1:150000, with data from South Africa and Iran estimating 1:140 000 and 1:1000000 respectively, although underreporting is a problem.
2,3 HAE treatment consists of 3 aspects: treatment of acute swelling episodes, short-term prophylaxis, and long-term prophylaxis.
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International guideline-recommended treatment options for on-demand therapies include: C1-INH concentrates (either plasma-derived or recombinant), bradykinin B2 receptor antagonist (icatibant), and the injectable plasma kallikrein inhibitor, ecallantide.
1 Targeted therapies are prohibitively expensive and/or unlicensed in many low-and middle-income countries (LMIC); in fact, less than 20% of the global HAE population may have access to these therapies (calculation based on global prevalence and current product registration information). Solvent-detergent, frozen or freezedried plasma, which contains C1-INH, is thus the only on-demand therapy available for acute swelling episodes for patients with HAE in such settings.
Solvent-detergent, frozen or freeze-dried plasma is used in many countries for on-demand therapy, yet there is limited published data on efficacy and safety with a total of only 60 acute swelling episodes in patients with HAE treated with plasma therapy reported. [5] [6] [7] [8] Concerningly, it has been suggested that plasma therapy may worsen angioedema due to containing potentially harmful substrates. Prematta et al. found 12 case reports in the literature and reported 11 instances of fresh frozen plasma (FFP) use for acute swelling episodes at the Hershey Medical Centre, in which one patient showed no improvement, and two had transient worsening of symptoms that may or may not have been related to FFP. 5 Winnewisser et al. found no adverse reactions in 30 cases treated at their institution. 6 In addition to reviewing the same literature as Prematta, Tang, Chen and Zhang examined 4 unique episodes from 2 patients at the Peking Union Medical College Hospital, with 1 transfusion reaction. 7 Pekdemir et al. published 3 cases of HAE successfully treated with FFP, including 1 patient with an urticarial transfusion reaction that responded well to treatment. 8 Thus, there is very limited published data on plasma therapy for on-demand treatment of HAE despite widespread use. No direct comparative data is available between targeted and plasma therapy. We thus conducted a study to examine the efficacy and safety of FFP for acute swelling episode treatment of HAE in 2 LMICs where FFP is commonly used.
METHODS Study design and setting
A retrospective patient folder review, as well as registry data, was used to extract data on the management of acute swelling episodes in patients with HAE treated in 6 South African and 1 Iranian National Reference center for HAE management respectively. In South Africa, folders of known HAE patients at 6 independent treatment centers were reviewed. 1, 9 In Iran, HAE patients detailed in an Iranian HAE registry were reviewed. Additionally, in South Africa HAE patients treated in the private healthcare sector were contacted via email and asked to provide any information available regarding any acute swelling episodes of HAE treated with FFP. Recorded acute swelling episodes spanned a period from 2001 to 2017, the year in which the data were collected. infusion; need for endotracheal intubation before or after FFP; treatment other than FFP; FFP adverse events and if they necessitated treatment and/or stopping the FFP infusion.
The method of recording time-to-resolution between South Africa and Iran differed substantially. South Africa's time-to-resolution was based on the nursing notes from patient folders, while Iran, based on patient recall, included an initial and final time-t-resolution for some episodes. As a result, time-to-resolution is not comparable between countries.
Statistical analysis
Categorical variables were summarized as frequencies and percentages. Parametric and nonparametric continuous data are presented using mean AE standard deviation, and medians and interquartile ranges (IQR) respectively. Data were analyzed in Microsoft Excel and Stata 142 (Stata Corp., College Station, TX). (Fig. 2B) . Table 2 details the 5 treatment-emergent adverse events (TEAEs) to FFP infusion; 3 were grade 2, 1 was grade 3 and 1 was grade 4 according to the National Cancer Institute's common terminology criteria for adverse events (CTCAE).
RESULTS
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All reactions necessitated stopping FFP infusions but were successfully treated and no fatalities occurred. The overall rate of transfusion reactions was 5%. There was no difference in adverse reactions necessitating treatment interruption between SA and Iran. However, one Iranian patient, who had experienced adverse reactions to FFP prior to the acute swelling episodes recorded in this review, and the 23-year-old female patient listed as one of the TEAEs, received premedication with antihistamine with/without corticosteroids prior to subsequent FFP infusions, and this was successful in preventing subsequent TEAEs. Premedication was given for a total of 14 of the reported episodes in the Iranian cohort. Table 3 shows the health provider estimated cost of hospitalization and FFP treatment for an acute swelling episode in a patient with HAE in South Africa (A) and Iran (B), using an ingredients approach. In South Africa the cost of treatment was between USD369 and USD791 using the median dose of FFP, with the differences related to hospital length of stay. Similarly, in Iran, the cost of treatment was between USD275 and USD550. (1) FFP is effective, although the time-to-resolution is considerably slower than reported for targeted therapies; (2) FFP has a TEAE rate of~5%, and premedication may reduce TEAEs; (3) setting-specific differences in acute HAE management and FFP use exist including speed of access to FFP therapy, treatment thresholds, dosing and time-to-resolution, and hospital length of stay; and (4) direct healthcare costs of FFP treatment with prolonged hospital length of stay approaches that of targeted therapy increasingly available through global access initiatives.
DISCUSSION
Our study of 98 acute HAE episodes treated with FFP across two LMICs is a substantive increase to the published literature evaluating the use of plasma therapy in acute HAE. In both South Africa and Iran, FFP therapy led to resolution in all but 2 cases (2%). Time-to-resolution was a median of 4 hours; consistent with existing data 7 but nearly double that reported for targeted therapiesincluding plasma-derived and recombinant C1-inhibitor, and icatibant.
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In addition, in contrast to targeted therapy, FFP therapy cannot be administered at home, nor is it immediately available on arrival to hospital as FFP specific to the patient's blood group must be ordered. In our study patients waited a median of 2 hours from admission to the start of plasma therapy. There is no clear recommendation about the per kilogram dosing for FFP in the literature, with estimates of 1-4 units or 20mLs/kg of FFP being effective 5 ; notably in our study 280 mL (1 unit) and 400 mL (2 units) of FFP were required in the majority of cases in Iran and South Africa respectively (estimated as less than 10mLs/kg given the majority were adults >40 kgs).
FFP use is safe for the majority of patients, but serious adverse events (SAEs) can occur. In our study there were 5% TEAEs, including one SAE (life-threatening anaphylaxis); similar to that reported in the HAE literature (3.3%) [5] [6] [7] [8] ; and from other studies of FFP use in the general population (3.4%). 16 In comparison, there was no or a very low rate of SAEs reported for trials of plasma-derived C1-inhibitor (0.19% of a total of 3196 infusions 17 ); and in the bradykinin-receptor antagonist trials (no SAEs in FAST-1, 2 or 3 [18] [19] [20] ). Two Iranian patients, 1 with past adverse reactions to FFP and 1 with a TEAE captured in Table  2 , were given antihistamine or corticosteroid prophylaxis prior to 14 subsequent acute episodes of FFP infusion without developing further TEAE; this suggests that premedication may be effective in reducing the incidence of TEAE in HAE patients receiving FFP infusions.
Prescribing practices for FFP use in acute HAE are based on a limited evidence base and consequently local practice is based on expert experience. This is the first study to compare FFP use for acute HAE in two LMICs. Substantial differences were noted including: (1) the anatomical locations of angioedema resulting in presentation to emergency care (South Africa higher facial and Iran higher abdominal episodes); (2) speed of access to hospital treatment (slower in South Africa); (3) proportion of hospitalized episodes treated with FFP (fewer in South Africa); (4) FFP single unit volume and hence initial dosing used; (5) reported time-to-resolution, and (6) hospital length of stay. There are a number of possible explanations for these differences. There was a weak correlation between longer time to access FFP treatment and time-to-resolution. Delay in the administration of FFP treatment (and lower dose units) may contribute to adverse events in the South Africa setting.
2,21 Notably, a higher proportion of SA (5) than Iranian (1) patients required intubation prior to FFP therapy. Iranian patient feedback also indicated that a shorter stay in hospital was due to: a preference to leave the hospital quickly to attend to other commitments; a feeling that no effective treatment was provided at the hospital; and a sense that physicians did not take problems seriously, especially in the initial stage of an acute swelling episode. Finally, given the retrospective nature of the study, recall bias may also have contributed. These differences highlight a need for HAE experts in LMICs to produce a consensus document on the use of plasma therapy for HAE.
The major argument for the use of FFP or solvent-detergent plasma in LMIC settings is the high cost of targeted therapies. However, our ingredients costing data indicate that when all direct costs such as hospitalization and doctor time are included, the total cost to public or private healthcare funders is substantial. Global access initiatives, such as the one driven by HAE International, 23 will increasingly mean that targeted therapies can be accessed more affordably (~USD800/adult treatment dose). If these products could be administered at home in LMIC, they may be cost neutral for healthcare funders and yet save patients substantial indirect cost; in 2019 the annual indirect costs for HAE patients in the USA were estimated to be USD52600.
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Local indirect costing is not available for either South Africa or Iran, but from our clinical experience we know that for certain indigent patients, even the cost burden of transport to and from emergency care is a significant economic burden.
This study has a number of strengths including the largest number of acute swelling episodes treated with FFP, as well as the inclusion of two different LMIC treatment settings. However, its major limitation remains that it was a retrospective study. There were thus missing data and possible recall bias. There may also have been differences in interpretation that could have affected study findings; for instance the time-to-resolution of symptoms which may have been recorded by some as the time to the start of symptoms resolution and not to that of complete resolution -patient notes often lacked clarity in this regard. Every effort was made to interrogate nursing charts to ensure accurate data and to limit missing information.
CONCLUSION
In summary, our study indicates that FFP is an effective and relatively safe therapy for on-demand treatment of swelling attacks in patients with HAE. The logistics of administration, the need to access hospital services, a slower time-to-resolution and consequent prolonged hospitalization, and the higher TEAE rate mean that targeted therapies remain preferable. Considerable differences in practice are evident, and to standardize treatment would be of considerable benefit where FFP may remain the only available therapy for many affected patients. Local experts should also conduct setting specific costings to motivate to public and private health care funders that, given improved pricing and global access programs, targeted therapy may, in fact, have a net economic benefit. Ideally a head-to-head comparison of a targeted versus a plasma-product in an LMIC with robust economic analysis would help provide a robust evidence base. 
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